Drug Search Results
More Filters [+]

PF-3864086

Alternative Names: pf-3864086, pf3864086, pf 3864086
Latest Update: 2010-01-08
Latest Update Note: Clinical Trial Update

Product Description

TRPV1 antagonist

Mechanisms of Action: TRPV1 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-3864086

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers|Pain Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B0361006

P1

Completed

Pain Unspecified|Healthy Volunteers

2008-12-01

Recent News Events

Date

Type

Title